https://doi.org/10.4081/monaldi.2022.2281
Tuberculosis endemicity and BCG vaccination: Protection against COVID-19
Submitted: March 30, 2022
Accepted: June 13, 2022
Published: June 24, 2022
Accepted: June 13, 2022
Abstract Views: 907
PDF: 243
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The coronavirus disease 2019 (COVID-19) has affected different countries in a differential manner. The host susceptibility and host factors are important parameters for this variability. This study aimed to assess the effect of tuberculosis (TB) endemicity and Bacille Calmette-Guerin (BCG) coverage on COVID-19. Available data regarding TB incidence, BCG coverage (as per the World Health Organization), and COVID-19 incidence of 168 countries as of 19th September 2021was collected. Countries were divided into four cohorts based upon annual TB incidence and BCG coverage and COVID-19 incidence and case fatality rates were compared using the Kruskal-Wallis test. Countries with low TB incidence and low BCG coverage had the highest COVID-19 incidence per lac population. However, no significant difference was seen in COVID-19 cases fatality rate. Higher TB incidence and BCG coverage were associated with lesser incidence of COVID-19. This result paves the way for research into pathogenesis and host immune response in COVID-19.
Pahuja S, Madan M, Mittal S, et al. Weather parameters and COVID-19: A Correlational analysis. J Occup Environ Med 2021;63:69–73.
DOI: https://doi.org/10.1097/JOM.0000000000002082
Madan M, Pahuja S, Mohan A, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public Health 2020;185:91–2.
DOI: https://doi.org/10.1016/j.puhe.2020.05.042
Miller A, Reandelar MJ, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020.03.24.20042937.
DOI: https://doi.org/10.1101/2020.03.24.20042937
World Health Organization. Coronavirus disease (COVID-19). Accessed: 2021 Oct 22. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
World Health Organization. Global Tuberculosis Report. Accessed: 2021 Oct 22. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports
Worldometer [Internet]. Coronavirus Cases (Live). Accessed: 5 September 2020. Available from: https://www.worldometers.info/coronavirus/
Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: Protection, pathology, and biomarkers. Mediators Inflamm 2015;2015:1–13.
DOI: https://doi.org/10.1155/2015/854507
Boppana TK, Mohan A, Madan K, et al. Candidate immunomodulators for COVID-19: Heat-killed Mycobacterium w and BCG vaccine. Adv Respir Med 2021;89:350-1.
DOI: https://doi.org/10.5603/ARM.a2021.0043
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38:1–9.
Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. Activate: Randomized clinical trial of BCG vaccination against infection in the elderly. Cell 2020;183:315-323.e9.
DOI: https://doi.org/10.1016/j.cell.2020.08.051
Clinicaltrials.gov [Internet]. Identifier: NCT04475302, BCG vaccine in reducing morbidity and mortality in elderly individuals in COVID-19 hotspots in India; 2020 Jul 17 [cited 2022 May 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT04475302
Madan M, Baldwa B, Raja A, et al. Impact of latent tuberculosis on severity and outcomes in admitted COVID-19 patients. Cureus 2021;13:e19882.
DOI: https://doi.org/10.7759/cureus.19882
How to Cite
Boppana, Tarun Krishna, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, and Randeep Guleria. 2022. “Tuberculosis Endemicity and BCG Vaccination: Protection Against COVID-19”. Monaldi Archives for Chest Disease 93 (1). https://doi.org/10.4081/monaldi.2022.2281.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- P. Malhotra, R. Agarwal, D. Gupta, A.N. Aggarwal, Successful management of ARDS with bronchopleural fistula secondary to miliary tuberculosis using a conventional ventilator , Monaldi Archives for Chest Disease: Vol. 63 No. 3 (2005): Pulmonary series
- B. Chakrabarti, P.D.O. Davies, Pleural tuberculosis , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- Lilit Gevorgyan, Ruzanna Grigoryan, Kostyantyn Dumchev, Kristina Akopyan, Anush Khachatryan, Eduard Kabasakalyan, Trdat Grigoryan, Marina Safaryan, Vardan Avagyan, Sayohat Hasanova, Alberto Matteelli, Factors associated with unfavourable treatment outcomes in people with HIV-associated tuberculosis in Armenia, 2015 to 2019 , Monaldi Archives for Chest Disease: Vol. 91 No. 1 (2021)
- Alexandru Stoichita, Andreea Dumitrescu, Ana Ciobanu, Cristian Oancea, Fildan Petronela, Radu Dabja, Kostyantyn Dumchev, Andrei Dadu, Beatrice Mahler-Boca, Kristina Akopyan, Depression and anxiety symptoms among people with rifampicin-resistant tuberculosis receiving in-patient care in the National Pulmonology Reference Institute in Romania , Monaldi Archives for Chest Disease: Vol. 91 No. 1 (2021)
- Govind Desai, Gopal Purohit, Hemant Borana, Kunal Deokar, Suresh Yogi, Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Federico Raimondi, Stefano Centanni, Fabrizio Luppi, Stefano Aliberti, Francesco Blasi, Paola Rogliani, Claudio Micheletto, Marco Contoli, Alessandro Sanduzzi Zamparelli, Marialuisa Bocchino, Paolo Busatto, Luca Novelli, Simone Pappacena, Luca Malandrino, Giorgio Lorini, Greta Cairoli, Fabiano Di Marco, Respiratory rate-oxygenation index on the 3rd day is the best predictor of treatment failure in COVID-19 patients , Monaldi Archives for Chest Disease: Early Access
- Deependra Kumar Rai, Surya Kant, Vatsal Bhushan Gupta, Paradoxical reaction in peripheral lymph node tuberculosis: a review for its prevalence, clinical characteristics, and possible treatment , Monaldi Archives for Chest Disease: Early Access
- Surabhi Panduranga Kodical, Rishabh Roy, Deekshitha Shetty, Nandakumar UP, Rajesh V, Sharad Chand, Reshma Kolar, Praneetha Jain, Exploring factors influencing the health-related quality of life of tuberculosis patients: a WHOQOL-BREF-based study , Monaldi Archives for Chest Disease: Early Access
- Ankita Mandal, Ajay Kumar Verma, Sujit Kumar Kar, Jyoti Bajpai, Surya Kant, Santosh Kumar, Ram Avadh Singh Kushwaha, Rajiv Garg, Anand Srivastava, Darshan Kumar Bajaj, Sanjeev Kumar Verma, Shyam Chand Chaudhary, A cross-sectional study to determine the psychological distress among pulmonary tuberculosis patients during COVID-19 pandemic , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Natalia Adamashvili, Kristina Akopyan, Nestani Tukvadze, Kostyantyn Dumchev, Yuliia Sereda, Irma Khonelidze, Giorgi Kuchukhidze, Factors associated with loss to follow-up among people with tuberculosis in the country of Georgia: a cohort study , Monaldi Archives for Chest Disease: Vol. 91 No. 1 (2021)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
